Provided by Tiger Trade Technology Pte. Ltd.

Yumanity Therapeutics, Inc.

1.89
0.0000
Volume:- -
Turnover:1.15M
Market Cap:2.93M
PE:-0.09
High:1.89
Open:1.89
Low:1.89
Close:1.89
52wk High:30.03
52wk Low:1.89
Shares:1.55M
Float Shares:1.25M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-20.9016
EPS(LYR):-26.8907
ROE:-168.67%
ROA:-42.93%
PB:0.54
PE(LYR):-0.07

Loading ...

Company Profile

Company Name:
Yumanity Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.